

***Look Who's Coming to
CSEP!***

Education Mission Statement

We are committed to advancing the highest standards of eye care through continuing education activities. The CSEP Semi-annual Scientific Education Programs are dedicated to improving and protecting our patient's vision and eye health by presenting advances in the diagnosis and treatment of eye disease. Our target audience includes ophthalmologists and their staff, including office managers and technicians. Activities range from didactic lectures to participatory activities, and whenever possible are approved for CME credit. We expect that our audience will incorporate best practices, as presented, into their daily practice. Specific competency, performance and patient outcome goals that will result from the program will be proposed by the presenters and evaluated by the participants.

-Revised 1/13/12



Welcome to

ANNUAL SCIENTIFIC EDUCATION PROGRAM
with Special AAO Twinning with
Guest Speakers from Australia


Physicians - Management - Technicians

June 8, 2012

Aqua Turf
Plantsville, Connecticut



Printed on 100% recycled paper using vegetable based ink.



SPECIAL ACKNOWLEDGMENT AND
THANKS
to our

TITANIUM EXHIBITORS
Alcon Laboratories, Inc.
Genentech

PLATINUM EXHIBITORS
Allergan
Regeneron Pharmaceuticals

GOLD EXHIBITORS
McLeod Optical
Merck
Precision Optical

SILVER EXHIBITORS

Abbott Medical Optics	Hoya Free-Form Company
American Express	IOP Ophthalmics
Angiotech/Sharpoint	IOP Practiceware, Inc.
Bausch & Lomb	Katena Instruments
Carl Zeiss Meditec	Lion Low Vision Center
Clarity Medical Systems	Lombart Instruments
Compulink Business Systems	Marco
Connecticut Library for the Blind	MDIntellSys
Essilor Labs	OMIC
Fallon Wellness Pharmacy	Ophthalmic Instrument Company
Fera Pharmaceuticals	Optovue
Heidelberg Engineering	SkinMedica
	Tearlab
	WebForDoctors

PHYSICIANS PROGRAM

8:30 **Everything I Think I Know About
Correcting Astigmatism**

- Robert Osher, M.D.

Objective: To review the historical and contemporary approach to correcting astigmatism at the time of cataract surgery. This will include the current and future technology for the pre-operative selection of the optimal toric lens and the intra-operative alignment method.

9:15 **The Link Between Risk Management and
Quality of Care: What Have We Learned?
How Can we Improve?**

- Richard Abbott, M.D.

Objective: Understand how the analysis of ophthalmic claims data can lead to risk management recommendations and improvement in quality of care for patients.

10:00 **Interesting Masquerade Cases for the
Ophthalmologist**

- Jerry Shields, M.D.

Objective: At the end of this lecture the attendees will be able to better recognize ocular tumors and be able to differentiate them from benign conditions that resemble cancers.

PHYSICIANS PROGRAM

10:30 **Coffee Break- Vendor Expo Area**

11:00 **Adrenalized Eye Cases**

- Robert Osher, M.D.

Objective: A series of videos will showcase challenging cases and intra-operative complications. Surgical strategies for achieving successful outcomes will be demonstrated.

11:30 **Who Has a Right to Sight? Vision 2020 and What I Should do in My Own Practice?**

- Hugh Taylor, M.D., A.C.

Objective: For practitioners to be aware of the problem of preventable blindness worldwide and the global initiatives to address this. For practitioners to understand what they should do in their own practice to reduce the amount of unnecessary vision loss in their own community.

12:15 **Lunch - National Politics and Medicine - Update 2012 - Legislative Awards**

1:15 **Patients and Pioneers: A Photographic History of the Advance of Ophthalmology**

- Stanley Burns, M.D.

Objectives: General; To show how ophthalmologists

PHYSICIANS PROGRAM

working with the technology and knowledge of their time met the challenges of eye disease, diagnosis and treatment.-- The point that what we know and believe to be 'gospel' today may prove erroneous.

1:45 **Ophthalmologists as Global Citizens:
Opportunities in Leadership**

- Catherine Green, M.D., MBChB, FRANZ
CO, MMedSC

Objective: To provide an update on global collaboration initiatives in ophthalmic leadership; highlight opportunities for the future

2:15 **Clinical Pearls in the Management of
Corneal Lacerations**

- Richard Abbott, M.D.

Objective: To understand the principles for suturing corneal lacerations and how to minimize induced corneal astigmatism.

2:45 **Coffee Break - Vendor Expo Area - Poster
Awards**

3:15 **Recent Innovations Regarding Malignant
Ocular Tumors**

- Jerry Shields, M.D.

Objective: Upon completion of this presentation the attendees should have better knowledge of intraocular

PHYSICIANS PROGRAM

tumors and pseudotumors to apply to their practices and provide better patient care.

3:45 **Transforming Glaucoma Care: Can We Make the Leap to the Future?**

- Catherine Green, M.D., MBChB, FRANZ CO, MMedSC

Objectives: Highlight the challenges we face in provision of future glaucoma care; present results of an alternative collaborative model of glaucoma care in the setting of a tertiary referral eye hospital and training centre.

4:15 **CME Certificates and Door Prizes**

The Connecticut Society of Eye Physicians designates this educational activity for a maximum of 6.5 AMA PRA Category I Credit(s)[™].

Physicians should only claim credit commensurate with the extent of their participation in the activity.

The Connecticut Society of Eye Physicians is accredited by the Connecticut State Medical Society to sponsor continuing medical education for physicians.

SPEAKERS



RICHARD ABBOTT, M.D.

After completing his Bachelor of Science degree at Tufts University in Boston, Dr. Abbott earned his medical degree at the George Washington University School of Medicine in Washington, DC. He performed his residency at the California Pacific Medical Center in

San Francisco and was a Heed and Fight for Sight fellow at the Bascom Palmer Eye Institute in Miami. Dr. Abbott currently is the Thomas W. Boyden Health Sciences Professor of Clinical Ophthalmology at the University of California San Francisco and Research Associate at the Francis I. Proctor Foundation.

Dr. Abbott has served on the editorial boards of several ophthalmic journals and continues to lecture and publish on a variety of topics focusing primarily on corneal and external diseases of the eye, as well as quality of care, clinical practice guidelines, and medicolegal issues. He has authored or co-authored 88 publications and 32 book chapters and has delivered over 650 invited lectures and 19 named lectures. Dr. Abbott has received numerous honors, including the prestigious U.S. President's 25 year Volunteer Service Award, the International Distinguished Golden Service Award from the Chinese Academy of Ophthalmology, the Jose Rizal Medal for International Service to the Asia Pacific region, the AE Maumenee Pan American Medal for Distinguished

SPEAKERS

Service to Latin America, and the American Academy of Ophthalmology's Lifetime Achievement Award.

Dr. Abbott is the immediate Past President of the American Academy of Ophthalmology and the Past President of both the Pan American Association of Ophthalmology and the Pan American Ophthalmological Foundation. He is immediate past Chairman of the Board of OMIC and a former Director of the American Board of Ophthalmology. Dr. Abbott is a Board Director for the International Council of Ophthalmology and serves as Chairman of the Clinical Practice Guidelines Committee. He is a member of both the American Ophthalmological Society and Academia Ophthalmologica Internationalis. He lives in Mill Valley, California, with his wife, Cecilia. They have three children and five grandchildren.



STANLEY BURNS, M.D.

Stanley B. Burns, MD,FACS a New York City ophthalmologist and Clinical Professor of Medicine at NYU Langone Medical Center is an internationally distinguished author, curator, historian, collector, and archivist. His photographic collection established in 1975 consists of over one million vintage prints from 1840-1960, including about 70,000 medical photographs. It is considered the most comprehensive private early historic

SPEAKERS

photograph collection in the world. The emphasis of the collection is rare and unique photographs. In 1977 he began his writing career and founded The Burns Archive to share his photographic discoveries. From his collection he has written 43 photo-historical texts including 31 texts on medical subjects with a four volume series on Dermatology 1850-1950. He has been past president and curator of several medical historic institutions such as the Museum of the Foundation of the American Academy of Ophthalmology, Medical Archivists of New York, and the International Society of Physician Historians. He has curated over 50 exhibitions, written and produced a documentary on death & memorial practices, and his photographs have been used by Hollywood producers and directors in numerous films from Jacob's Ladder to The Others. The historic dermatology photographs have been used in exhibitions and texts worldwide from the Finnish military medical manual to an exhibition at Paris' Musee d'Orsay.



**CATHERINE GREEN, M.D., MBChB, FRANZCO,
MMEdSC**

Dr. Catherine Green is an ophthalmologist in Melbourne with a subspecialty interest in glaucoma. She undertook her ophthalmology training at the Royal Victorian Eye and Ear Hospital (RVEEH), Melbourne, and com-

SPEAKERS

pleted a Glaucoma Fellowship at the Western Eye Hospital, London in 2001, before working as a Consultant in the Glaucoma Unit at Moorfields Eye Hospital. She returned to Melbourne in late 2002, and since then, has worked in private practice and in the Glaucoma Clinic at the RVEEH. Her other professional interests include medico-legal aspects of medicine, risk management, medical education and ophthalmology in developing countries. She has worked in Nepal, Myanmar, Timor Leste, and most recently in Fiji, where she where she will continue to contribute as a member of the visiting teaching faculty at the Pacific Eye Institute.

Cathy is extensively involved in the activities of the Royal Australian and New Zealand College of Ophthalmologists (RANZCO). She has been an examiner for the College since 2004, and became Chair of the Ophthalmic Sciences Court of Examiners in 2009. Having served as the Treasurer and Chair of the Victorian Branch of RANZCO, and as a Councillor for several years, she was appointed to the Board of Directors of RANZCO last year. She has also recently been appointed to the Board of Directors of the Centre for Eye Research Australia (CERA). In addition to her clinical practice, she is the Deputy Medical Executive for Invivo, one of Australia's five medical indemnity companies.

As a graduate of the inaugural APAO Leadership

SPEAKERS

Development Program 2009-2010, Cathy has been instrumental in the continuation of the program as Program Director.



ROBERT OSHER, M.D.

Robert H. Osher, M.D. is Professor of Ophthalmology at the College of Medicine of the University of Cincinnati and Medical Director Emeritus of the Cincinnati Eye Institute. His practice is limited to cataract and implant surgery by

referral.

Dr. Osher served his residency at the Bascom Palmer Eye Institute and completed three fellowships in Miami and at the Wills Eye Hospital in Philadelphia. He has received the Heed Ophthalmic Fellowship Award, the Maumenee Award, the Sheets Award, the Rayner Award from England, the Canon Award from Japan, the Senior Academy Honor Award and the Lifetime Achievement Award from AAO, the Lim Award from China, the Gold Medal Award from Australia, the Mooney Award from Ireland, the Nordan Lifetime Achievement Award, the Kelman Award from Greece, the Excellence Award from Canada and a lectureship bearing his name in Argentina. The American Society of Cataract and Refractive Surgery has given Dr. Osher its

SPEAKERS

two highest honors, the prestigious Binkhorst Medal and the Innovator's Award. He also has received the Kelman Award, the highest honor given to a cataract surgeon by the American Academy of Ophthalmology.

Dr. Osher has achieved worldwide recognition in cataract surgery. He has designed many of the contemporary intraocular lenses and instruments used in cataract surgery, in addition to developing new techniques in this subspecialty. Dr. Osher's surgical videos have won more than 25 first-prize honors at the American, European, Asian and South American Cataract Societies including 3 Grand Prizes at ASCRS and ESCRS. His lectures have been presented to implant societies in more than 35 countries and he has co-authored several textbooks in his subspecialty. He serves as editor of the Video Journal of Cataract and Refractive Surgery, the Video Textbook of Viscosurgery, and International Advances in Phacoemulsification and has published more than 250 videos and peer-reviewed articles. He has served on the executive committee of the Outpatient Surgery Society and as the international editor of the Brazilian journal FOCO. He is a Reviewer for the Journal of Cataract and Refractive Surgery and serves on the editorial boards of six additional Journals.

SPEAKERS

Besides his interest in cataract surgery, Dr. Osher has been a proud coach of more than 70 youth baseball and basketball teams reaching the National Championships in each sport. He served as the ophthalmic consultant for the Cincinnati Reds during the 1990's. Dr. Osher has also published 17 children's stories raising money with the proceeds for charitable organizations.



JERRY A. SHIELDS, M.D.

Jerry A. Shields, M.D. is director of the Oncology Service at Wills Eye Institute and Professor of Ophthalmology Thomas Jefferson University in Philadelphia. He was a resident at Wills Eye Hospital and completed fellowships in ophthalmic pathology and retinal surgery. For more than 30 years, he has been active in the care of patients with ocular tumors and in clinical research related to tumors of the eyelids, conjunctiva, intraocular structures, and orbit. He has authored or co-authored more than 1200 articles in scientific journals and more than 500 textbook chapters for a total of more than 1700 scientific publications. He has authored or co-authored 13 major textbooks and has given 1500 national and international lectures, including 66

SPEAKERS

named lectures. He has also received 28 national and international academic awards for his contributions.

Dr. Shields has served on the editorial boards of 13 journals. He was the organizer and first president of the international Society of Ocular Oncology, president of the Ophthalmic Club of Philadelphia, and president of the Wills Eye Medical Staff, and president of the Macula Society in 2009. Dr. Shields is married to Dr. Carol Shields also practices on the Oncology Service of Wills Eye Institute and has made many similar contributions. They have 7 children ranging from ages 23 to 11 years of age.



PROFESSOR HUGH R. TAYLOR A.C., M.D., FRANZCO

Melbourne Laureate Professor Hugh Taylor is the Harold Mitchell Professor of Indigenous Eye Health at the University of Melbourne. Previously he was Head of the Department of Ophthalmology at the University of Melbourne and the Founding Director of the Centre for Eye Research Australia. Prior

to that, he was a Professor of Ophthalmology at the Wilmer Institute at the Johns Hopkins University in Baltimore with joint appointments in the Departments of Epidemiology and International Health.

Professor Taylor's research interests include blindness prevention strategies, infectious causes of blindness and the relationship between medicine, public health and health

SPEAKERS

economics. His current work particularly focuses on Aboriginal eye health and trachoma.

Professor Taylor has written 23 books and reports including a recent book on trachoma, and more than 600 scientific papers. He has received multiple international awards and prizes including 13 named lectures.

In 2001, he was made a Companion in the Order of Australia.

He is Vice President of the International Agency for the Prevention of Blindness, Treasurer of the International Council of Ophthalmology and Deputy Chairman of Vision 2020 Australia.

**Connecticut Society of Eye Physicians
Financial Interest Disclosure Report 6-8-12**

<i>Speaker</i>	<i>Financial Interest Received</i>
Richard Abbott, M.D.	None
Stanley Burns, M.D	None
Catherine Green, M.D.	None
Robert Osher, M.D.	Alcon, AMO, Bausch & Lomb, BVI, Clarity, Haag-Streit, SMI, Zeiss
Jerry Shields, M.D.	None
Professor Hugh Taylor, A.C.	None

CSEP AWARDS

David Parke Leadership

Joyce Lagnese, Esq.; Michael Rigg, Esq.; Frank Santoro, Esq.

Star Awards

Senator Edward Meyer

Senator Anthony J. Musto

Senator Terry B. Gerratana

Representative Prasad Srinivasan, M.D.

Representative Peter Tercyak

Representative Pat Widlitz

Andrew J. Packer, M.D.

David Emmel, M.D.

Vision Awards

Robert H. Osher, M.D.

for innovation and scientific contributions to ophthalmology

Hugh Taylor, M.D.

*for glaucoma research including Vision 2020
and the eradication of preventable blindness worldwide*

David Parke Award Recipients



JOYCE A. LAGNESE

Ms. Lagnese is one of the founding principals of the Hartford Law firm of DanaherLagnese, PC, where she serves as head of the Medical Malpractice Defense Unit. She is a high honors graduate from the State University of New York and obtained her law degree with honors in 1980 from Hofstra University School of Law. Her practice concentration is high exposure medical practice defense litigation. For over three decades, she has defended medical malpractice cases throughout Connecticut on behalf of physicians from every medical specialty, and has successfully tried to verdict a large number of medical malpractice cases including claims of wrongful death and permanent injury. Her practice also includes representation of medical practitioners and institutions in administrative proceedings before the Connecticut Department of Public Health.

Ms. Lagnese has been an invited lecturer and Keynote Speaker to various local and regional medical societies, physicians organizations and hospitals on medico-legal topics and is co-author of a textbook on Connecticut Medical Malpractice. She has also been an advocate in the Connecticut State Legislature for malpractice tort reform.



MICHAEL G. RIGG has been practicing law in Connecticut since 1996. For the first six years of his career, Michael worked in a law firm representing plaintiffs in personal injury cases and criminal defendants in both state and federal court. In 2002, Michael joined the law firm of O'Brien, Tanski & Young, LLP, and

has focused his practice almost exclusively on representing physicians and hospitals who have sued for medical malpractice. His practice also includes representing clients in appeals before the Appellate and Supreme Courts of Connecticut.



FRANK SANTORO

For the past 23 years, Frank has been a member of DanaherLagnese law firm where he specializes primarily in appellate practice. He has been counsel of record in approximately 100 reported cases. He is the co-author (with Joyce Lagnese and Cal

Anderson) of Connecticut Medical Malpractice.

Prior to the Danaher firm, Frank was an Army Officer and an Assistant United States Attorney.

Frank is a graduate of Georgetown and the University of London. He lives in Deep River. He is married to Jane Cavanaugh and has a son Christopher.

**CSEP Business Agenda Luncheon
June 8, 2012**

- I Call to Order - 12:30 David Emmel, M.D.
- II Approval of the Jan 13, 2012 Minutes
- III President's Report - David Emmel, M.D.
 - a. Special Guest Recognition
 - b. New Members Recognition
 - c. CSEP Special Positions
 - 1. AAO Councilor- Jeff Sandler, M.D.
 - 2. CAC for National Government Services -
Beth Rocco, M.D.
 - 3. CSEP Legislative Chairs- Steven Thornquist, M.D.
and Bill Ehlers, M.D.
 - 4. CSEP Education Chairs- Vincent deLuise, M.D. and
James Weisz, M.D.
 - 5. CSEP Membership Chair - David Emmel, M.D.
- IV Election of Officers
 - a. President - Edward Lim, M.D.
 - b. President-Elect - Ron Adelman, M.D.

- c. Secretary - David McCullough, M.D.
 - d. Treasurer - Seth Meskin, M.D.
 - e. Vice Chair of Exec Committee - Jim Tsai, M.D.
 - f. Immediate Past President - David Emmel, M.D.
- V Legislative Report (in packet)
- a. Certificate of Merit - Bill Malitsky
- VI Awards
- a. David Parke Leadership Award
 - b. Star Awards
- VII Education Update
- a. Vision Awards
 - b. Next Meeting Date - January 11, 2013
 - 1. Speakers
 - 2. Topics
 - c. Poster Exhibit
- VIII Treasurer's Report available September 1, 2012
- IX Adjournment
- X Introduction of Keynote Speaker

MANAGEMENT PROGRAM

- 8:00 Registration – Continental Breakfast in Vendor Expo
- 8:30 **Making the Computer Cool Again with Free and Bargain Tech Tools that Your Office Needs Today**
- Beth Ziesenis- Author of *"The Best Free & Low-Cost Online Tools and Apps for Medical Practices."*
- 10:00 **Coffee Break**
- 10:30 **The Best Free & Low-Cost Online Tools and Apps for Medical Practices**
- Beth Ziesenis
- 12:00 **Lunch- Wagon Room – Keynote speaker**
- 1:15 **The Medico-Legal Climate in CT – The Road to Sanity**
- Joyce Lagnese, Esq. , partner Danaher Lagnese, PC

MANAGEMENT PROGRAM

- 1:35 **The Danger of Social Media in the Work Place**
- Wendy Kroll, J.D., June Sullivan, J.D.,
Halloran & Sage, LLP
- 2:00 **Lessons Learned from Malpractice Claims**
- Paul Weber, J. D., V. P. Risk Management,
OMIC
- 2:30 **Coffee Break**
- 3:00 **How to Get Your M.D.s Involved in Leadership Roles**
- Edward Lim, M.D., Catherine Green, M.D.
- 3:30 **Major Issues in Medical Practice
Integration with Hospitals: Taking the Big Step**
- Kennedy Hudner, J.D., Murtha Culina
- 4:30 **Certificates and Door Prizes**

TECHNICIANS PROGRAM

8:00 Registration/Continental Breakfast/Vision Expo

Clinical Challenges in Glaucoma

8:30 Introductions & Case Presentations

8:40 David Hill, M.D.

9:00 Hugh Taylor, M.D.

9:20 Catherine Green, M.D.

9:40 Panel Discussion with Questions and Answers

10:00 Organic Tea, Coffee and Muffin Break

Clinical Challenges in Cornea

10:30 Introductions & Case Presentations

10:40 Richard Abbott, M.D.

11:00 Peter Shriver, M.D.

11:20 Seth Meskin, M.D.

TECHNICIANS PROGRAM

11:40 Panel Discussion with Questions and Answers

12:00 Lunch

Clinical Challenges in Retina

1:00 Introductions

1:10 Ron Margolis, M.D.

1:30 Jerry Shields, M.D.

2:10 Panel Discussion with Questions and Answers

Challenging Surgical Cases in Ophthalmology

2:30 Robert Osher, M.D.

3:10 Questions and Answers

3:20 Coffee Break

Global Challenges in Ophthalmology

3:50 Bill Ehlers, M.D.

4:30 Questions and Answers

4:40 Overall Assessment and Final Review

5:00 Certificates Door Prizes

This course has been awarded 6.5 JCAHPO CE Credits,
AOC 6.50 CEC Credits and OPS pending.



Optical Company Inc.
Committed to Independent Eyecare

Ask us about our full-service, in-house Crizal® processing lab!

Dan Mataboni, Branch Manager
Rod MacLeod, Sales Rep

451 Meriden Road
Waterbury, CT 06705
800.873.5367



Crizal and Varilux are registered trademarks and Crizal Advance and TD2 are trademarks of Essilor International S.A.

Crizal®

TD2®

VARILUX®



P.O. Box 280023

East Hartford, CT 06128-0023

Phone (860) 289-6023

National WATS: (800) 842-8622

Fax: (860) 289-0164 ~ Fax

WATS (800) 441-8866

www.precision-optical-co.com

e-mail precision.optical@snet.net

PRECISION OPTICAL CO.

is proud to support the CSEP

Precision is also proud of its
independence—over sixty years!

We have supported Connecticut
doctors for many years and will continue
to service the association and its members
for many years to come.

Please call us for all you optical needs.

We specialize in servicing almost
all products.



For patients with decreased tear production presumed to be due to ocular inflammation associated with chronic Dry Eye

Don't Wait Until Their Own Real Tears Are Too Low
Prescribe RESTASIS®

Only RESTASIS® is approved to help your patients make more of their own real tears

Indications and Usage: RESTASIS®

Ophthalmic Emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.

Important Safety Information

Contraindications: RESTASIS® is contraindicated in patients with active ocular infections and in patients with known or suspected hypersensitivity to any of the ingredients in the formulation.

Warning: RESTASIS® has not been studied in patients with a history of herpes keratitis.

Precautions: The emulsion from one individual single-use vial is to be used immediately after opening for administration to one or both eyes, and the remaining contents should be discarded immediately after administration. Do not allow the tip of the vial to touch the eye or any surface, as this may contaminate the emulsion. RESTASIS® should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to the administration of the emulsion.

Adverse Reactions: The most common adverse event was ocular burning (upon instillation)—17%. Other events reported in

1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring).

Please see brief Prescribing Information on adjacent page.

To find local average co-pays

Scan your way to
RESTASIScopay.com
with the ScanLife app



Text "SCAN" to 43598 to download the scanner

 **ALLERGAN**

©2014 Allergan, Inc., Irvine, CA 92618
Made in Israel by Allergan, Inc. 440321018


Restasis
Cyclosporine Ophthalmic Emulsion 0.05%
RESTASISPROFESSIONAL.COM

RESTASIS®

(cyclosporine ophthalmic emulsion) 0.05%
Sterile, Preservative-Free

INDICATIONS AND USAGE

RESTASIS® ophthalmic emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.

CONTRAINDICATIONS

RESTASIS® is contraindicated in patients with active ocular infections and in patients with known or suspected hypersensitivity to any of the ingredients in the formulation.

WARNING

RESTASIS® ophthalmic emulsion has not been studied in patients with a history of herpes keratitis.

PRECAUTIONS

General: For ophthalmic use only.

Information for Patients

The emulsion from one individual single-use vial is to be used immediately after opening for administration to one or both eyes, and the remaining contents should be discarded immediately after administration.

Do not allow the tip of the vial to touch the eye or any surface, as this may contaminate the emulsion.

RESTASIS® should not be administered while wearing contact lenses. Patients with decreased tear production typically should not wear contact lenses. If contact lenses are worn, they should be removed prior to the administration of the emulsion. Lenses may be reinserted 15 minutes following administration of RESTASIS® ophthalmic emulsion.

Carcinogenesis, Mutagenesis, and Impairment of Fertility

Systemic carcinogenicity studies were carried out in male and female mice and rats. In the 78-week oral (diet) mouse study, at doses of 1, 4, and 16 mg/kg/day, evidence of a statistically significant trend was found for lymphocytic lymphomas in females, and the incidence of hepatocellular carcinomas in mid-dose males significantly exceeded the control value.

In the 24-month oral (diet) rat study, conducted at 0.5, 2, and 8 mg/kg/day, pancreatic islet cell adenomas significantly exceeded the control rate in the low dose level. The hepatocellular carcinomas and pancreatic islet cell adenomas were not dose related. The low doses in mice and rats are approximately 1000 and 500 times greater, respectively, than the daily human dose of one drop (28 µL) of 0.05% RESTASIS® BID into each eye of a 60 kg person (0.001 mg/kg/day), assuming that the entire dose is absorbed.

Cyclosporine has not been found mutagenic/genotoxic in the Ames Test, the V79-HGPRT Test, the micronucleus test in mice and Chinese hamsters, the chromosome-aberration tests in Chinese hamster bone-marrow, the mouse dominant lethal assay, and the DNA-repair test in sperm from treated mice. A study analyzing sister chromatid exchange (SCE) induction by cyclosporine using human lymphocytes *in vitro* gave indication of a positive effect (i.e., induction of SCE).

No impairment in fertility was demonstrated in studies in male and female rats receiving oral doses of cyclosporine up to 15 mg/kg/day (approximately 15,000 times the human daily dose of 0.001 mg/kg/day) for 9 weeks (male) and 2 weeks (female) prior to mating.

Pregnancy-Teratogenic Effects

Pregnancy category C.

Teratogenic Effects: No evidence of teratogenicity was observed in rats or rabbits receiving oral doses of cyclosporine up to 300 mg/kg/day during organogenesis. These doses in rats and rabbits are approximately 300,000 times greater than the daily human dose of one drop (28 µL) of 0.05% RESTASIS® BID into each eye of a 60 kg person (0.001 mg/kg/day), assuming that the entire dose is absorbed.

Non-Teratogenic Effects: Adverse effects were seen in reproduction studies in rats and rabbits only at dose levels toxic to dams. At toxic doses (rats at 30 mg/kg/day and rabbits at 100 mg/kg/day), cyclosporine oral solution, USP, was embryonic and fetotoxic as indicated by increased pre- and postnatal mortality and reduced fetal weight together with related skeletal retardations. These doses are 30,000 and 100,000 times greater, respectively, than the daily human dose of one drop (28 µL) of 0.05% RESTASIS® BID into each eye of a 60 kg person (0.001 mg/kg/day), assuming that the entire dose is absorbed. No evidence of embryofetal toxicity was observed in rats or rabbits receiving cyclosporine at oral doses up to 17 mg/kg/day or 30 mg/kg/day, respectively, during organogenesis. These doses in rats and rabbits are approximately 17,000 and 30,000 times greater, respectively, than the daily human dose.

Offspring of rats receiving a 45 mg/kg/day oral dose of cyclosporine from Day 15 of pregnancy until Day 21 post partum, a maternally toxic level, exhibited an increase in postnatal mortality; this dose is 45,000 times greater than the daily human topical dose, 0.001 mg/kg/day, assuming that the entire dose is absorbed. No adverse events were observed at oral doses up to 15 mg/kg/day (15,000 times greater than the daily human dose).

There are no adequate and well-controlled studies of RESTASIS® in pregnant women. RESTASIS® should be administered to a pregnant woman only if clearly needed.

Nursing Mothers

Cyclosporine is known to be excreted in human milk following systemic administration but excretion in human milk after topical treatment has not been investigated. Although blood concentrations are undetectable after topical administration of RESTASIS® ophthalmic emulsion, caution should be exercised when RESTASIS® is administered to a nursing woman.

Pediatric Use

The safety and efficacy of RESTASIS® ophthalmic emulsion have not been established in pediatric patients below the age of 16.

Geriatric Use

No overall difference in safety or effectiveness has been observed between elderly and younger patients.

ADVERSE REACTIONS

The most common adverse event following the use of RESTASIS® was ocular burning (17%). Other events reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring).

Rx Only



ALLERGAN

Based on package insert 71876US148 Revised February 2010

©2010 Allergan, Inc.

Irvine, CA 92612, U.S.A.

® marks owned by Allergan, Inc. APC10XG10

U.S. Patent 5,474,959

Made in the U.S.A.

SAVE THE DATE

Friday January 11, 2013



PAUL S. KOCH, M.D. Cataract and Lens Implant Surgery, Refractive Surgery
Dr. Koch is a Founder and the Medical Director of Koch Eye Associates. His specialty is Cataract, Lens Implantation, and Refractive Surgery.



CYNTHIA MATTOX, M.D.
Dr. Mattox is an Associate Professor and Vice-Chair of the Department of Ophthalmology at Tufts University School of Medicine, where she is the Director of the Glaucoma and Cataract Service at the New England Eye Center in Boston, MA.

RICH MOLTEN author, golf pro and speaker to discuss Motivation, Focus and How Not to Burn Out of Ophthalmology.



MICHAEL E. SNYDER, M.D. specializes in diseases and surgery of the front of the eye, including small-incision, topical anesthesia cataract surgery. His special interests include traumatic cataract surgery, iris repair, corneal transplantation, and refractive surgery.



SUNIL K. SRIVASTAVA, M.D.

Dr. Srivastava did his Fellowship at Duke University Medical Center Vitreo-retinal Surgery Durham, NC and in 2005 completed another fellowship at the National Institutes of Health Uveitis/ Medical Retina Bethesda, MD.

Dr. Srivastava is currently a staff physician at the Cole Eye Institute Cleveland Clinic, in Cleveland, OH.



MICHAEL WALL, M.D. is a professor of Neurology and Ophthalmology at the University of Iowa. His undergraduate and medical school education was at Tulane University; his neurology residency at Washington University in St. Louis and fellowship at Massachusetts Eye and Ear infirmary. As a neuro-ophthalmologist he is

involved in patient care, teaching and research.



PAUL WEBER, J.D. is a lawyer/risk manager and currently serves as Ophthalmic Mutual Insurance Company's (OMIC) Vice President Risk Management/Legal. OMIC is the sponsored professional liability carrier of the American Academy of Ophthalmology and provides medical professional liability insurance to over

4,400 ophthalmologists. Mr. Weber guides the development of risk management and loss prevention services and is also responsible for planning and directing the overall development of the legal and regulatory functions of OMIC.



RUTH D. WILLIAMS, M.D. Is President of the American Academy of Ophthalmology. She served a term as the Secretary for Member Services and a term as trustee-at-large on the Academy's Board of Trustees. She led the Academy's programs for Young Ophthalmologists and Senior Ophthalmologists.

The CSEP Annual Scientific Education Programs are an opportunity for ophthalmologists to identify and discuss critical issues facing their profession. These programs are designed to present recent advances in the diagnosis and treatment of eye disease, offering symposia, scientific papers and videos. The CSEP programs are designed to meet the clinical and educational needs of its members and the objectives set forth by the CSEP education committee.

*Vincent de Luise, M.D.
CSEP Education Chair*

CSEP Leadership

President

Edward Lim, M.D.

Immediate Past President

David Emmel, M.D.

President-Elect

Ron Adelman, M.D.

Secretary

David McCullough, M.D.

Treasurer

Seth Meskin, M.D.

Education Committee Co-Chairs

Vincent deLuise, M.D.

James Weisz, M.D.

Members

Ron Adelman, M.D.

Jim Tsai, M.D.

Ed Lim, M.D.

Andrew Packer, M.D.

Martin Wand, M.D.

CAC Representative

Elizabeth Rocco, M.D.

Legislative Committee Co-Chairs

Steve Thornquist, M.D.

William Ehlers, M.D.

Members

Timothea Ryan, M.D.

David McCullough, M.D.

Sarit Patel, M.D.

Managed Care Committee

Vicente Diaz, M.D.

David Emmel, M.D.

Zachary Klett, M.D.

Wendy Kroll, J.D.

Membership Chair

David Emmel, M.D.

Executive Director

Debbie Osborn

Lobbyists

Jim Paolino

Bill Malitsky

Tricia Dineen-Prebe

Lisa Winkler

Executive Committee

Members

Vice-Chair- Jim Tsai

Ron Adelman, M.D.

Joseph Bentivegna, M.D.

Robert Block, M.D.

Vincent deLuise, M.D.

Vicente Diaz, M.D.

William Ehlers, M.D.

David Emmel, M.D.

Paul Gaudio, M.D.

Gregory Haffner, M.D.

Zachary Klett, M.D.

Edward Lim, M.D.

Delia Manjoney, M.D.

Ron Margolis, M.D.

David McCullough, M.D.

Seth Meskin, M.D.

Andrew Packer, M.D.

David Parke, M.D. Life

Sarit Patel, M.D.

Mary Gina Ratchford

Elizabeth Rocco, M.D.

Timothea Ryan, M.D.

Jeffrey Sandler, M.D.

Anish Shah, M.D.

Douglas Shore, M.D.

James Tsai, M.D.

Steven Thornquist, M.D.

James Weisz, M.D.

Yale Resident

Ninani Kombo, M.D.

Special Thanks to Edward Lim, M.D.
from an anonymous donor in the
amount of \$600 for the benefit of CSEP.

Notes:

Notes:

